Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance

LIFECORE BIOMEDICAL, INC. DE

2026-Q1 EPS reported -$0.43 revenue$23,193,000

Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.
Net loss $15.0M ($0.43 loss per diluted share) vs $14.8M loss year ago.
Adjusted EBITDA $1.0M, down $4.7M from $5.7M; operating expenses cut 52%.
Signed three new commercial site transfer programs in Q1; reaffirms full-year 2026 guidance.
Liquidity $38.1M (cash $20.8M, revolver $17.3M); free cash flow $3.6M.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001005286-26-000018
form_type: 8-K
ticker: LFCR
cik: 0001005286
company_name: LIFECORE BIOMEDICAL, INC. DE
filed_at: 2026-05-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:31.781852+00:00
generated_at: 2026-05-14T22:26:26.793402+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.72
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001005286-26-000018
json_url: https://secwatch.observer/filing/0001005286-26-000018.json
markdown_url: https://secwatch.observer/filing/0001005286-26-000018.md
text_url: https://secwatch.observer/filing/0001005286-26-000018.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/0001005286-26-000018-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/lndc-20260506.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001005286-26-000018

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.